Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350150 | 0.87 | GAA (0.50) | GAASMN1; SMN2ALDH1A1CHRM1TSHR | |
| SCHEMBL12036169 | 0.83 | EPHX2 (0.42) | GAASMN1; SMN2ALDH1A1KDM4EPKM | |
| SCHEMBL13366346 | 0.83 | GAA (0.55) | GAASMN1; SMN2ALDH1A1CHRM1TSHR | |
| SCHEMBL27392467 | 0.83 | NOS2 (0.48) | GAASMN1; SMN2KDM4ECYP1A2TDP1 | |
| SCHEMBL8277480 | 0.83 | GAA (0.55) | GAASMN1; SMN2ALDH1A1CHRM1TSHR | |
| SCHEMBL8162857 | 0.82 | GAA (0.53) | GAASMN1; SMN2ALDH1A1CHRM1TSHR | |
| SCHEMBL7358278 | 0.81 | GAA (0.57) | GAASMN1; SMN2ALDH1A1CHRM1TSHR | |
| SCHEMBL190928 | 0.81 | CYP1A2 (0.48) | SMN1; SMN2KDM4ECYP1A2TDP1 | |
| SCHEMBL2745870 | 0.79 | GAA (0.51) | GAASMN1; SMN2ALDH1A1CHRM1TSHR | |
| SCHEMBL18519658 | 0.79 | EPHX2 (0.43) | GAASMN1; SMN2KDM4ECYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | claimed |
| EP-2536731-A1 | SUBSTITUTED SPIROINDOLINONES | F. Hoffmann-La Roche AG (CH) | 2012-12-26 | — | — | EP | claimed |
| US-8288431-B2 | Substituted spiroindolinones | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | claimed |
| EP-2245033-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | claimed |
| EP-2245033-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-03 | — | — | EP | claimed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | claimed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | claimed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | claimed |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | LG CHEM, LTD. (KR) | 2026-05-26 | — | — | US | disclosed |
| CN-114901653-B | Novel amide derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2024-11-22 | — | — | CN | disclosed |
| EP-4074701-B1 | NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | LG CHEMICAL LTD (KR) | 2023-12-13 | — | — | EP | disclosed |
| US-20230101389-A1 | NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-03-30 | — | — | US | disclosed |
| EP-4074701-A1 | NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | Lg Chem, Ltd. (KR) | 2022-10-19 | — | — | EP | disclosed |
| CN-114901653-A | Novel amide derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2022-08-12 | — | — | CN | disclosed |
| EP-0290985-B1 | 1-[n-(2-Alkylthio-10H-phenothiazin-10-yl)alkyl]-4-benzoylpiperidines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-07-08 | — | — | EP | disclosed |
| US-4812456-A | TREATMENT OF PAIN AND PSYCHOSIS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1989-03-14 | — | — | US | disclosed |
| EP-0290985-A1 | 1-[n-(2-Alkylthio-10H-phenothiazin-10-yl)alkyl]-4-benzoylpiperidines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-11-17 | — | — | EP | disclosed |
| US-4110459-A | ANALGESIC | AMERICAN HOECHST CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4101663-A | ANTIHYPERTENSIVES | AMERICAN HOECHST CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
| US-4046900-A | TRANQUILIZERS, HYPOTENSIVES, ANALGESICS | AMERICAN HOECHST CORPORATION (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | GAA 3155/4885SMN1; SMN2 4777/4885ALDH1A1 4082/4885 |
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | GAA 4863/4885SMN1; SMN2 4526/4885ALDH1A1 3412/4885 |
| US-20230101389-A1 | NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | DGAT2, DGAT1, MOGAT2 | GAA 343/4885SMN1; SMN2 4708/4885ALDH1A1 696/4885 |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | DGAT2, DGAT1, DLAT | GAA 593/4885SMN1; SMN2 4700/4885ALDH1A1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.